Malignant Mesothelioma Epidemiology Forecast, Diagnosis, Treatment Options | DelveInsight

Malignant Mesothelioma Epidemiology Forecast, Diagnosis, Treatment Options | DelveInsight

“Malignant Mesothelioma – Epidemiology Forecast to 2030”

DelveInsight has launched a new report on ‘Malignant Mesothelioma – Epidemiology Forecast to 2030’

DelveInsight’s ‘Malignant Mesothelioma – Epidemiology Forecast to 2030‘ report delivers an in-depth understanding of the disease, historical and forecasted Malignant Mesothelioma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Some of the key facts of the Report:

  1. The annual incidence of Mesothelioma in the United States is estimated to be approximately 3,300 cases per year.
  2. Around 70% of MM develops from documented asbestos exposure, usually after a 30–40 years latency period.
  3. Malignant Mesothelioma (MM) is a rare tumor with an incidence
  4. In Europe, the average incidence of MM is 20 per million inhabitants/year

 

“As per DelveInsight’s analysts, men are more often affected than women, and the incidence in males in the US is 1.5 per 100,000 per year.”

 

Malignant Mesothelioma (MM) is a relatively rare but aggressive form of cancer most frequently a result of inhaling asbestos arising from the membrane covering the lungs and the inner side of the ribs. The symptoms of MM include breathlessness, cough, chest pain, fatigue, fevers, persistent cough, loss of appetite and unexplained weight loss, swollen figures and constipation. There is an extremely poor prognosis and a vast majority of MM patients who are diagnosed in an advanced stage.

The major subtypes of MM, which are defined as per the histology (appearance under the microscope) includes Epithelial MM (the most common form and makes up about 60% of all cases), Sarcomatoid MM (comprises about 10% of all cases and these tumors display a somewhat more aggressive behavior) and mixed/biphasic (20%). The remainder of cases are comprised of the Mixed, or Biphasic variant of MM that contains elements of both Epithelial and Sarcomatoid MM.

Malignant Mesothelioma (MM) is a rare, but severe form of cancer, with an incidence that varies significantly within and among different countries around the world. It develops in about one to two persons per million of the general population, leading to thousands of deaths every year worldwide. Asbestos represents the predominant etiological factor, with approximately 70% of cases of MM with well‐documented occupational exposure to asbestos, with the exposure time, on average greater than 40 years.

 

“As per DelveInsight insights, the incidence varies between 7 per million in Japan.”

 

Request a Free Sample Report @  https://www.delveinsight.com/sample-request/malignant-mesothelioma-epidemiology-forecast

 

Scope of the Report

  • The Malignant Mesothelioma report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Malignant Mesothelioma Epidemiology Report and Model provide an overview of the risk factors and global trends of Malignant Mesothelioma in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Malignant Mesothelioma in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Malignant Mesothelioma
  • The report provides the segmentation of the Malignant Mesothelioma epidemiology

 

KOL- Views

We interview, KOLs and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

 

Request a Free Sample Report @  https://www.delveinsight.com/sample-request/malignant-mesothelioma-epidemiology-forecast

 

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Malignant Mesothelioma?
  • What are the key findings pertaining to the Malignant Mesothelioma epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Malignant Mesothelioma across the 7MM during the forecast period (2017-2030)?
  •  Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Malignant Mesothelioma?
  • What are the currently available treatments of Malignant Mesothelioma?

 

Reasons to buy

  • The Malignant Mesothelioma Epidemiology report will allow the user to –
  • Develop business strategies by understanding the trends shaping and driving the global Malignant Mesothelioma market
  • Quantify patient populations in the global Malignant Mesothelioma market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Malignant Mesothelioma therapeutics in each of the markets covered
  • Understand the magnitude of Malignant Mesothelioma population by its epidemiology
  • The Malignant Mesothelioma Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

 

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

 

Related Reports:

 

Malignant Mesothelioma  – Pipeline Insights, 2020

The Malignant Mesothelioma report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Malignant Mesothelioma across the complete product development cycle, including all clinical and nonclinical stages.

Malignant Mesothelioma – Market Insights, Epidemiology, and Market Forecast-2030

The Malignant Mesothelioma market report provides current treatment practices, emerging drugs, Malignant Mesothelioma market share of the individual therapies, current and forecasted Malignant Mesothelioma market Size from 2017 to 2030 segmented by seven major markets.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Vinita Rakheja
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/